| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.70▲ | 2.70▲ | 2.69▲ | 2.88▼ | 3.01▼ |
| MA10 | 2.70▲ | 2.69▲ | 2.67▲ | 2.98▼ | 2.93▼ |
| MA20 | 2.70▲ | 2.66▲ | 2.71▲ | 3.02▼ | 2.93▼ |
| MA50 | 2.69▲ | 2.79▼ | 2.92▼ | 2.99▼ | 2.70▲ |
| MA100 | 2.67▲ | 2.94▼ | 3.05▼ | 2.94▼ | 2.37▲ |
| MA200 | 2.70▲ | 3.05▼ | 2.97▼ | 2.62▲ | 5.01▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | 0.018▲ | 0.017▲ | -0.055▼ | -0.015▼ |
| RSI | 63.747▲ | 51.532▲ | 38.588▼ | 41.845▼ | 48.320▼ |
| STOCH | 52.778 | 91.348▲ | 76.876 | 15.938▼ | 39.611 |
| WILL %R | 0.000▲ | 0.000▲ | -20.833▲ | -89.385▼ | -75.085▼ |
| CCI | 72.414 | 119.512▲ | 114.019▲ | -182.407▼ | -23.728 |
|
Wednesday, September 09, 2026 04:00 AM
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/09/26 | 2.69 | 2.72 | 2.625 | 2.715 | 2,044,048 |
| 10/09/26 | 2.77 | 2.77 | 2.62 | 2.65 | 2,548,618 |
| 09/09/26 | 3.06 | 3.06 | 2.77 | 2.77 | 2,962,094 |
| 08/09/26 | 3.20 | 3.215 | 3.01 | 3.03 | 2,272,661 |
| 04/09/26 | 3.04 | 3.23 | 3.04 | 3.23 | 1,386,300 |
| 03/09/26 | 3.09 | 3.13 | 3.00 | 3.08 | 1,378,047 |
| 02/09/26 | 3.09 | 3.23 | 2.98 | 3.08 | 1,673,999 |
| 01/09/26 | 3.00 | 3.155 | 2.98 | 3.07 | 1,225,212 |
| 31/08/26 | 3.125 | 3.1355 | 3.025 | 3.06 | 2,074,056 |
| 28/08/26 | 3.25 | 3.4099 | 3.15 | 3.16 | 3,267,144 |
|
|
||||
|
|
||||
|
|